Overview of therapeutic vaccination approaches for cancer

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 8, 2003, Pages 1-8

  Berinstein, Neil ^a  

^a Aventis Pasteur   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCEA CEA; AUTOANTIGEN; B7 ANTIGEN; BCG VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN; INTERLEUKIN 12; INTERLEUKIN 4; MAGE 3.A1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; MALIGNANT TRANSFORMATION; MELANOMA; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW; STIMULATION; TUMOR CELL; VACCINATION;

EID: 0042303768     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00231-8     Document Type: Review

References (13)

1. Berinstein NL: Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J Clin Oncol 8:2197-2207, 2002
2. Kaisho T, Alria S: Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589:1-13, 2002
3. Mareckova H, Ravdan A, Fucikova T, et al: Detection of the production of intracellular cytokines by T lymphocytes using flow cytometry: Methodologic problems. Epidemiol Mikrobiol Imunol 51:111-118, 2002
4. Kwok WW, Ptacek NA, Liu AW, et al: Use of class II tetramers for identification of CD4+ T cells. J Immunol Methods 268:71-81, 2002
5. Foon KA, John WJ, Chakraborty M, et al: Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 3:1267-1276, 1997
6. von Mehren M, Arlen P, Tsang KY, et al: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patient with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 6:2219-2228, 2000
7. Vermorken JB, Claessen AME, van Tinteran H, et al: Active specific immunotherapy for stage II and stage III human colon cancer: A randomized trial. Lancet 353:345-350, 1999
8. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129-3135, 1997
9. Fong L, Hou Y, Rivas A, et al: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98:8809-8814, 2001
10. Slack R, Ley L, Chang P, et al: Association between CEA-specific T cell responses (TCR) following treatment with vaccinia-CEA (V) and Alvac-CEA (A) and survival in patients (Pts) with CEA-bearing cancers. Proc Am Soc Clin Oncol 20:272A, 2001 (abstr 1086)
11. Marchand M, van Baren N, Weynants P, et al: Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230, 2000
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
13. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-333, 1998